XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 12 - Segment Information
 6 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

During fiscal year 2022, we realigned our financial reporting segments to reflect how management evaluates the business and allocates resources. The acquisition of Agena expanded our presence further into the life sciences tools market and provided an impetus for the creation of our new Clinical Genomics reportable segment. The strategic shift in our business also resulted in a change to the way we manage other business units, and as a result, our historical Instruments and Continuous Monitoring reportable segments have been combined to create Calibration Solutions. Prior year amounts presented have been reclassified to conform to current year presentation. Our change in financial reporting segments has not resulted in any change to previously reported consolidated amounts.

 

   

Three Months Ended September 30,

    

Six Months Ended September 30,

  
   

2022

    

2021

    

2022

    

2021

  

Revenues:

                                

Clinical Genomics

   $ 18,435     $ -     $ 32,940     $ -  

Sterilization and Disinfection Control

     16,964       14,033       31,738       29,183  

Biopharmaceutical Development

     12,144       10,555       23,111       19,432  

Calibration Solutions

     11,206       11,252       21,413       22,145  

Total revenues (a)

   $ 58,749     $ 35,840     $ 109,202     $ 70,760  
                                 

Gross profit

                                

Clinical Genomics

   $ 10,641     $ -     $ 18,490     $ -  

Sterilization and Disinfection Control

     12,199       10,486       22,967       21,914  

Biopharmaceutical Development

     7,557       6,601       14,634       11,293  

Calibration Solutions

     6,007       6,128       11,671       12,240  

Reportable segment gross profit

     36,404       23,215       67,762       45,447  

Corporate and Other (b)

     (18 )     (75 )     (35 )     (96 )

Gross profit

   $ 36,386     $ 23,140     $ 67,727     $ 45,351  

Reconciling Items:

                                

Operating expenses

     32,391       18,939       68,326       38,027  

Operating income (loss)

     3,995       4,201       (599 )     7,324  

Nonoperating expense (income), net

     611       (342 )     1,429       1,363  

Earnings (loss) before income taxes

   $ 3,384     $ 4,543     $ (2,028 )   $ 5,961  

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
 

(b)

 Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

 

   

September 30,

    

March 31,

  
   

2022

    

2022

  

Clinical Genomics

   $ 12,600     $ 11,802  

Sterilization and Disinfection Control

     2,864       2,176  

Biopharmaceutical Development

     5,214       4,495  

Calibration Solutions

     7,361       6,133  

Total inventories

   $ 28,039     $ 24,606